Evidence map›Paper›PMID 35267120›Full record

ArticleApplied biochemistry and biotechnology2022

MicroRNA-148a Inhibits Hepatocellular Carcinoma Cell Growth via Epithelial-to-Mesenchymal Transition and PI3K/AKT Signaling Pathways by Targeting Death Receptor-5.

Naipeng Zhang, Jian Zhou, Yang Zhou, Fulong Guan

Abstract read
PubMed Publisher
In one paragraph

Article in Applied biochemistry and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Naipeng ZhangDepartment of General Surgery, Hongqi Hospital affiliated to Mudanjiang Medical University, No.5, Tongxiang Road, Aimin District, Heilongjiang Province, 157000, Mudanjiang City, China.
Jian ZhouDepartment of General Surgery, Hongqi Hospital affiliated to Mudanjiang Medical University, No.5, Tongxiang Road, Aimin District, Heilongjiang Province, 157000, Mudanjiang City, China.
Yang ZhouDepartment of Stomatology, Hongqi Hospital affiliated to Mudanjiang Medical University, 157000, Mudanjiang City, China.
Fulong GuanDepartment of General Surgery, Hongqi Hospital affiliated to Mudanjiang Medical University, No.5, Tongxiang Road, Aimin District, Heilongjiang Province, 157000, Mudanjiang City, China. guanfulongdr@163.com.
Mudanjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to investigate the role of microRNA-148a (miR-148a) in hepatocellular carcinoma (HCC) metastasis and explore its potential mechanism in HCC cells. Expression levels of miR-148a were measured using qRT-PCR in 120 HCC tissue samples and two HCC cell lines. Migration and invasion assays were used to determine the role of miR-148a in HCC cells. Flow cytometry was used to access the effect of miR-148a on cell cycle of HCC cells. Western blot was performed to analyze the effect of miR-148a on epithelial-to-mesenchymal transition (EMT) and PI3K/AKT signaling pathways in HCC cells. Luciferase reporter assay was conducted to explore the downstream targets and biological function of miR-148a in HCC cells. The results showed that level of miR-148a was significantly downregulated in both HCC tissue and plasma samples in HCC patients. A higher level of miR-148a was positively correlated with better survival time and prognosis of HCC patients. Transfection of miR-148a inhibited the proliferation, migration and invasion of HCC cell lines. Transfection of miR-148a arrested HCC cells at S phase and promoted apoptosis of HCC cells. Death receptor-5 (DR-5) was identified as a direct target of miR-148a in HCC cell lines. Western blot and qRT-PCR analyses showed that miR-148a upregulated EMT and downregulated PI3K/AKT signaling pathways in HCC cell lines. In conclusion, data in the current study indicate that miR-148a inhibits HCC cells growth via downregulation of EMT and PI3K/AKT signaling pathways by targeting death receptor. These data suggest that miR-148a may serve as a therapeutic target for HCC cancer therapy in the future.

Indexed as

Carcinoma, HepatocellularEpithelial-Mesenchymal TransitionLiver NeoplasmsMicroRNAsReceptors, TNF-Related Apoptosis-Inducing LigandCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionMicroRNAsMIRN148 microRNA, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptors, TNF-Related Apoptosis-Inducing LigandAKTDR-5EMTHCCmiR-148aPI3K

Identifiers

PMID35267120
OpenAlexW4221052993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.